

January 30, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Intimation of Execution of Memorandum of Understanding for Acquisition of 100% stake in M/s Curexis Ventures Private Limited

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, Zota Health Care Limited (the “Company”), would like to inform you that we have entered into a Memorandum of Understanding (“MOU”) with M/s Curexis Ventures Private Limited (“Curexis”), Mr. Sushant Bhattacharya and Mr. Swagato Mukherjee the existing shareholders of Curexis, for acquisition of 100% stake by acquiring 1,00,000 equity shares of Curexis.

Consequent to the proposed acquisition, the Company would have 100% shareholding in Curexis.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed herewith as ***Annexure-I***.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Particulars	Details
Name(s) of parties with whom the agreement is entered	M/s Curexis Ventures Private Limited (“Curexis”), Mr. Sushant Bhattacharya and Mr. Swagato Mukherjee the existing shareholders of Curexis.
Purpose of entering into the agreement	To expand the footprint of the Company in the retail generic pharmacy chain segment.
Shareholding, if any, in the entity with whom the agreement is executed	N.A.
Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Acquisition of 100% stake by acquiring 1,00,000 equity shares of Curexis.
Whether, the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship	No
Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Yes, the proposed transaction with the Shareholders of the Curexis would fall within related party transactions and the same shall be done at arm’s length basis.
In case of issuance of shares to the parties, details of issue price, class of shares issued	N.A.
Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	N.A.
In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s)	N.A.
a) name of parties to the agreement	--
b) nature of the agreement	--
c) date of execution of the agreement	--
d) details of amendment and impact thereof or reasons of termination and impact thereof	--